ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more
ALK-Abelló A/S (AKBLF) - Total Assets
Latest total assets as of September 2025: $8.47 Billion USD
Based on the latest financial reports, ALK-Abelló A/S (AKBLF) holds total assets worth $8.47 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ALK-Abelló A/S - Total Assets Trend (2005–2024)
This chart illustrates how ALK-Abelló A/S’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ALK-Abelló A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
ALK-Abelló A/S's total assets of $8.47 Billion consist of 40.0% current assets and 60.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.1% |
| Accounts Receivable | $861.00 Million | 10.4% |
| Inventory | $1.72 Billion | 20.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.33 Billion | 16.1% |
| Goodwill | $463.00 Million | 5.6% |
Asset Composition Trend (2005–2024)
This chart illustrates how ALK-Abelló A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALK-Abelló A/S's current assets represent 40.0% of total assets in 2024, a decrease from 87.6% in 2005.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2024, down from 80.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 2.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 20.8% of total assets.
ALK-Abelló A/S Competitors by Total Assets
Key competitors of ALK-Abelló A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
ALK-Abelló A/S - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - ALK-Abelló A/S generates 0.67x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, ALK-Abelló A/S generates $9.88 in net profit.
ALK-Abelló A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.56 | 2.95 | 2.27 |
| Quick Ratio | 1.35 | 1.47 | 1.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.23 Billion | $ 2.12 Billion | $ 1.31 Billion |
ALK-Abelló A/S - Advanced Valuation Insights
This section examines the relationship between ALK-Abelló A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.20 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | 22.6% |
| Total Assets | $8.25 Billion |
| Market Capitalization | $2.61 Billion USD |
Valuation Analysis
Below Book Valuation: The market values ALK-Abelló A/S's assets below their book value (0.32 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ALK-Abelló A/S's assets grew by 22.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ALK-Abelló A/S (2005–2024)
The table below shows the annual total assets of ALK-Abelló A/S from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.25 Billion | +22.60% |
| 2023-12-31 | $6.73 Billion | +6.63% |
| 2022-12-31 | $6.31 Billion | +8.20% |
| 2021-12-31 | $5.83 Billion | +4.80% |
| 2020-12-31 | $5.56 Billion | +1.24% |
| 2019-12-31 | $5.50 Billion | +12.95% |
| 2018-12-31 | $4.87 Billion | -1.88% |
| 2017-12-31 | $4.96 Billion | +3.31% |
| 2016-12-31 | $4.80 Billion | +12.86% |
| 2015-12-31 | $4.25 Billion | +24.36% |
| 2014-12-31 | $3.42 Billion | +4.62% |
| 2013-12-31 | $3.27 Billion | -0.43% |
| 2012-12-31 | $3.28 Billion | -2.15% |
| 2011-12-31 | $3.35 Billion | +18.52% |
| 2010-12-31 | $2.83 Billion | +6.67% |
| 2009-12-31 | $2.65 Billion | +4.53% |
| 2008-12-31 | $2.54 Billion | -10.03% |
| 2007-12-31 | $2.82 Billion | +1.15% |
| 2006-12-31 | $2.79 Billion | -59.67% |
| 2005-12-31 | $6.92 Billion | -- |